Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sam Chang MD, MBA

Sam S. Chang MD, MBA

Professor, Department of Urology; Patricia and Rodes Hart Professor of Urologic Surgery; Chief Surgical Officer, Vanderbilt Ingram Cancer Center; Chief, Division of Urologic Oncology, Vanderbilt University, Nashville, Tennessee

After completing his education and training at Princeton University, Vanderbilt University, and Memorial Sloan-Kettering, Dr. Chang returned to Nashville and is currently Professor of Urologic Surgery. Focusing on urologic oncology and education, he has led efforts in integration of evidence-based medicine in clinical pathways, enhanced guidelines formulation, and improved cancer staging as chair of the AJCC GU Staging Panel and as a CoC member.  He was the vice-chair of the AUA Guidelines on Noninvasive Bladder Cancer and the facilitator for the AUA Renal Cancer Follow-up Guidelines.  Dr. Chang has authored more than 200 original publications. For his academic efforts, he received the SUO’s first-ever Distinguished Service Award, the CaPCURE Young Investigator Award, and has been twice named a Journal of Urology’s Best Reviewer.  Dr. Chang was recently honored with the American Urological Association Gold Cystoscope Award.

Recent Contributions to PracticeUpdate:

  1. Changes in Glomerular Filtration Rate After Neoadjuvant Chemotherapy Prior to Nephroureterectomy for UTUC
  2. Role of Lymphadenectomy During Radical Cystectomy for Non–Muscle Invasive Bladder Cancer
  3. Artificial Intelligence System for the Detection of Bladder Cancer via Cystoscopy
  4. European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer
  5. Initial Experience With Novel Single-Use Disposable Ureteroscopy
  6. Site of Metastatic Recurrence Impacts Prognosis in Patients With High-Grade Upper Tract Urothelial Carcinoma
  7. Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients With Bladder Cancer
  8. Effects of the Hospital Readmissions Reduction Program on Radical Cystectomy Readmissions
  9. Non-Urothelial Variant Histology and Oncological Outcomes Following Radical Cystectomy
  10. Distal Ureter Management During Nephroureterectomy

Recently Updated